P9R is a peptide with antiviral activity.1 It inhibits viral replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, influenza A subtypes H1N1 and H7N9, and rhinovirus in plaque reduction assays (IC50s = 0.9, 2.2, 4.2, 0.6, 0.9, and 5.7 ?g/ml, respectively). In vivo, P9R (50 ?g/animal three times over two days) increases survival and reduces H1N1 particle-forming units (PFUs) in the lungs to a similar extent as the influenza neuraminidase inhibitor zanamivir in H1N1-infected mice.
References:
[1]. Zhao, H., To, K.K.W., Sze, K.-H., et al.A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2Nat. Commun.11(1)4252(2020).